The relationship between BSP mRNA expression and 25(OH)D/OPG in peripheral blood of newly diagnosed T2DM patients with different bone mass

Sitong Fan1, Zhe Wang2, Qi Li2, Liya Luo2, Yuyu Zhu2, Yan Yang1

1Department of Endocrinology, Affiliated Hospital of Zunyi Medical University, Guizhou Province, China
2Department of Endocrinology, Zunyi Medical College Affiliated Hospital, Zunyi, China

Abstract

Introduction: The objective of the study was to detect the levels of osteoprotegerin (OPG) and 25-hydroxyvitamin D [25(OH)D], as well as the expression of bone sialoprotein (BSP) mRNA, in the peripheral blood of patients with newly diagnosed type 2 diabetes mellitus (T2DM) under different bone mass conditions, and to explore its role and significance in the development process of T2DM combined with osteoporosis (OP).

Material and methods: A total of 225 patients hospitalised in the Endocrinology Department and General Department from May 2017 to May 2018 were enrolled and categorised into five groups: the pure T2DM group (group A, 45 patients), the bone mass reduction group (group B, 45 patients), the T2DM + bone mass reduction group (group C, 45 patients), the OP group (group D, 45 patients), and the T2DM + OP group (group E, 45 patients); meanwhile, age-matched healthy subjects undergoing physical examination in our hospital were collected as the normal control group (group NC, 45 cases). Logistic regression analysis was used to analyse the influencing factors of bone mass in patients with T2DM.

Results: Compared with group B, the expression levels of glycated haemoglobin (HbA1c), 25(OH)D, N-terminal propeptide of type I procollagen (PINP), fasting plasma glucose (FPG), fasting plasma insulin (FINS), high-density lipoprotein cholesterol (HDL-C), and BSP mRNA were significantly increased while OPG and b-collagen degradation products (b-CTX) were significantly decreased in group A.

Conclusions: The expression of BSP mRNA and the decrease of 25(OH)D and OPG in peripheral blood may participate in the development of diabetes and osteoporosis.

Key words: type 2 diabetes mellitus; bone mass; bone sialoprotein; 25 hydroxy vitamin D; osteoprotegerin

Introduction

Diabetes mellitus (DM) is a group of metabolic diseases characterised by increased levels of chronic blood sugar caused by insulin secretion or defects [1]. Osteoporosis (OP) is a systemic bone disease characterised by decreased bone mass, decreased bone strength, increased bone fragility, and proneness to fracture [2]. Bone sialoprotein (BSP) is a marker of bone metabolism that activates osteoblasts or osteoblast-like cells, guides bone mineralisation, and promotes bone formation [3]. Osteoprotegerin (OPG) is a glycoprotein secreted by osteoblasts, which plays an important role in maintaining normal bone metabolism [4]. Osteoprotegerin can significantly inhibit the differentiation and maturation of osteoclasts and bone resorption activity, and it might induce apoptosis and necrosis [5]. Vitamin D (VD) is closely related to the development of T2DM and OP. Its main function is to maintain normal blood calcium and phosphorus levels and promote normal bone mineralisation [6]. 25-hydroxyvitamin D [25(OH)D] is stably present in the body and is a commonly used indicator for the observation of VD level. Studies have found that VD receptors are expressed on islet b cells; VD is involved in glucose metabolism, and VD deficiency impairs human glucose regulation and increases the risk of T2DM [7]. Under physiological conditions, VD is one of the essential substances for maintaining normal blood sugar and glucose-stimulated insulin secretion [8]. The relationship between BSP mRNA expression in peripheral blood and 25(OH)D/OPG in type 2 DM (T2DM) patients with different bone mass has not been reported in China or abroad. Therefore, this study intended to compare the expression of BSP mRNA in peripheral blood of healthy controls with that in T2DM patients with different bone masses, in order to explore the possible mechanisms of BSP mRNA, 25(OH)D, and OPG in regulating glycometabolism, lipid metabolism, and bone mass, thus providing new ideas for early clinical prevention and treatment of DM and OP.
Material and methods

Subjects
A total of 225 patients hospitalised in the Endocrinology Department and General Department from May 2017 to May 2018 were enrolled and categorised into five groups: the pure T2DM group (group A, 45 patients), the bone mass reduction group (group B, 45 patients), the T2DM + bone mass reduction group (group C, 45 patients), the OP group (group D, 45 patients), and the T2DM + OP group (group E, 45 patients); meanwhile, age/age-matched healthy subjects undergoing physical examination in our hospital were collected as the normal control group (group NC, 45 cases). The subjects in group NC all had normal bone density and glucose tolerance (by oral glucose tolerance test). The T2DM patients were in compliance with the diagnostic criteria of WHO Diabetes (1999). Informed consent was obtained from all subjects, and the study was approved by the Ethics Committee.

Inclusion criteria
There were four inclusion criteria:
1 — females with menopause over one year and males aged ≥ 60 years, meeting the criteria for newly diagnosed T2DM;
2 — with no history of organ or endocrine disease, or acute/chronic complications of diabetes, with normal liver and kidney function;
3 — the subjects in group NC had no family history of diabetes and osteoporosis;
4 — without a history of smoking or alcohol abuse.

Exclusion criteria
There were six exclusion criteria:
1 — with previous severe heart, liver, kidney, or other organ or endocrine diseases;
2 — used drugs that may affect sugar, fat, or bone metabolism in the past month;
3 — with a clear history of infection in the past two weeks;
4 — suffered from rheumatoid arthritis, thyroid, parathyroid, adrenal gland, gonads, bone tumours, pituitary, or other diseases affecting bone metabolism; with fractures;
5 — used drugs that may affect bone metabolism (sex hormones, bisphosphonates, glucocorticoids, high-dose calcium, VD preparations, etc.) in the past six months;
6 — with a history of smoking or a long history of heavy drinking.

Diagnostic criteria
The diagnostic criteria for OP refer to the diagnostic criteria for the diagnosis and treatment of primary OP issued by the Osteoporosis and Bone Mineral Diseases Society of the Chinese Medical Association [9]. According to the DXA measurement results, the bone density being lower than and within the standard deviation of bone peak of healthy adults with the same sex and race is defined as normal; the reduction ranging from 1- to 2.5-fold standard deviation is defined as OP; the degree of bone density reduction meets the diagnostic criteria of OP, and the reduction equalling or more than 2.5-fold standard deviation is defined as OP; the degree of bone density reduction meets the diagnostic criteria of OP and severe OP is defined as OP simultaneously combing with one or more fragile fractures. Bone mineral density is usually expressed as T-Score, T-score = (measured value – peak bone density of normal young people with the same race and gender)/standard deviation of peak bone density of normal young people with the same race and gender. The diagnostic criterion of OP referring to the bone mineral density of central axis (lumbar vertebrae L1–4, femoral neck or total hip) or 1/3 of the distal radius based on DXA measurement is T-score ≤ –2.5.

Table 1. Specific primers used for real-time polymerase chain reaction (PCR)

<table>
<thead>
<tr>
<th>Primer</th>
<th>Primer sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSP</td>
<td>Upstream 5'-CAACGCCCCTGACCCAGCATAG-3'</td>
</tr>
<tr>
<td></td>
<td>Downstream 5'-GGCTGCCTTCGGCTTCATAG-3'</td>
</tr>
</tbody>
</table>

BSP — bone sialoprotein

Results

Comparison of general data and clinical biochemical indexes
1. The comparison of age, disease duration, gender, and BMI among groups showed no statistical significance (p > 0.05).
2. Compared with group B, the expression levels of HbA1c, 25(OH)D, PINP, FPG, FINS, and HDL-C were significantly increased while OPG and β-CTX were significantly decreased in group A (p < 0.05), but the difference in TC, TG, and HOMA-IR was not statistically significant (p > 0.05).
3. Compared with group C, the expressions of PINP, 25(OH)D, and HDL-C were significantly increased while OPG, β-CTX, FPG, and HbA1c were significantly decreased in group A (p < 0.05), but the difference in TC, TG, FINS, and HOMA-IR was not statistically significant (p > 0.05).

4. Compared with group D, the expression levels of HbA1c, PINP, 25(OH)D, FPG, HDL-C, and FINS were significantly increased while OPG and β-CTX were significantly decreased in group A (p < 0.05), but the difference in TC, TG, and HOMA-IR was not significantly different (p > 0.05).

5. Compared with group D, the expression levels of PINP, 25(OH)D, and HDL-C were significantly increased while OPG, β-CTX, FPG, and HbA1c were significantly decreased in group A (p < 0.05), but the difference in TC, TG, FINS, and HOMA-IR was not statistically significant (p > 0.05).

6. Compared with group NC, the expression levels of OPG, FPG, HbA1c, PINP, 25(OH)D, HDL-C, and FINS were significantly decreased while the expressions of 25(OH)D, HDL-C, and PINP were significantly decreased in group A (p < 0.05).

7. Compared with group C, the expression levels of PINP, 25(OH)D, and HDL-C were significantly increased while OPG, β-CTX, HbA1c, FPG, and FINS were significantly decreased in group B (p < 0.05), but the difference in TC, TG, and HOMA-IR was not statistically significant (p > 0.05).

8. Compared with group D, the expression levels of PINP, 25(OH)D, and HDL-C were significantly increased while OPG, β-CTX, and HbA1c were significantly decreased in group B (p < 0.05), but the difference in TC, TG, FINS, and HOMA-IR was not statistically significant (p > 0.05).

9. Compared with group E, the expression levels of PINP, 25(OH)D, and HDL-C were significantly increased while OPG, β-CTX, HbA1c, FPG, and FINS were significantly decreased in group B (p < 0.05), but the difference in TC, TG, and HOMA-IR was not statistically significant (p > 0.05).

10. Compared with group NC, the expression levels of OPG, FPG, HbA1c, PINP, 25(OH)D, HDL-C, and FINS were increased significantly while the expressions of 25(OH)D, HDL-C, and PINP were significantly decreased in group B (p < 0.05).

11. Compared with group D, the expression levels of HbA1c, PINP, 25(OH)D, FPG, HDL-C, and FINS were increased significantly while OPG and β-CTX were decreased significantly in group C (p < 0.05), but the difference in TC, TG, and HOMA-IR was not statistically significant (p > 0.05).

12. Compared with group E, the expression levels of PINP, 25(OH)D, and HDL-C were significantly increased while OPG, β-CTX, FPG, and HbA1c were significantly decreased in group C (p < 0.05), but there was no significant difference in TC, TG, FINS, and HOMA-IR (p > 0.05).

13. Compared with group NC, the expression levels of OPG, FPG, HbA1c, PINP, 25(OH)D, HDL-C, and FINS were significantly increased while 25(OH)D, HDL-C, and PINP were significantly decreased in group C (p < 0.05).

14. Compared with group E, the expression levels of PINP, 25(OH)D, and HDL-C were significantly increased while OPG, β-CTX, HbA1c, FPG, and FINS were significantly decreased in group D (p < 0.05), but the difference in TC, TG, and HOMA-IR was not statistically significant (p > 0.05).

15. Compared with group NC, the expression levels of PINP, 25(OH)D, HDL-C, and PINP were significantly decreased in group D (p < 0.05).

16. Compared with group NC, the expression levels of OPG, FPG, HbA1c, PINP, 25(OH)D, HDL-C, and FINS were significantly increased while 25(OH)D, HDL-C, and PINP were significantly decreased in group E (p < 0.05) (Tab. 2, Fig. 1).

**Level of BSP mRNA**

1. Compared with group B, BSP mRNA in the peripheral blood was significantly upregulated in group A (p < 0.05).

2. Compared with group C, BSP mRNA in the peripheral blood was significantly upregulated in group A (p < 0.05).

3. Compared with group D, BSP mRNA in the peripheral blood was significantly upregulated in group A (p < 0.05).

4. Compared with group E, BSP mRNA in the peripheral blood was significantly upregulated in group A (p < 0.05).

5. Compared with group NC, BSP mRNA in the peripheral blood was significantly downregulated in group A (p < 0.05).

6. Compared with group C, BSP mRNA in the peripheral blood was significantly upregulated in group B (p < 0.05).

7. Compared with group D, BSP mRNA in the peripheral blood was significantly upregulated in group B (p < 0.05).

8. Compared with group E, BSP mRNA in the peripheral blood was significantly upregulated in group B (p < 0.05).

9. Compared with group NC, BSP mRNA in the peripheral blood was significantly downregulated in group B (p < 0.05).
10. Compared with group D, BSP mRNA in the peripheral blood was significantly upregulated in group C (p < 0.05).

11. Compared with group E, BSP mRNA in the peripheral blood was significantly upregulated in group C (p < 0.05).

Table 2. Comparison of general data and biochemical indexes among groups (x ± s)

<table>
<thead>
<tr>
<th>Group</th>
<th>N (M/F)</th>
<th>Age (years)</th>
<th>BMI [kg/m²]</th>
<th>HbA₁c (%)</th>
<th>FPG [mmol/L]</th>
<th>PINP [ng/mL]</th>
<th>OPG [ng/L]</th>
<th>β-CTX [ng/mL]</th>
<th>TC [mmol/L]</th>
<th>TG [mmol/L]</th>
<th>LDL-C [mmol/L]</th>
<th>HDL-C [mmol/L]</th>
<th>HOMA-IR</th>
<th>25(OH)D [ng/mL]</th>
<th>FINS [uIU/mL]</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC (n = 45)</td>
<td>45 (25/20)</td>
<td>63.39 ± 3.24</td>
<td>22.33 ± 2.15</td>
<td>3.99 ± 0.35</td>
<td>4.92 ± 0.81</td>
<td>58.02 ± 12.96</td>
<td>149.03 ± 21.02</td>
<td>0.17 ± 0.11</td>
<td>4.81 ± 0.38</td>
<td>1.23 ± 0.39</td>
<td>2.33 ± 0.42</td>
<td>1.31 ± 0.30</td>
<td>1.98 ± 0.09</td>
<td>34.96 ± 2.39</td>
<td>9.09 ± 1.81</td>
</tr>
<tr>
<td>A (n = 45)</td>
<td>45 (20/25)</td>
<td>62.52 ± 2.39</td>
<td>24.31 ± 2.31</td>
<td>8.31 ± 1.72</td>
<td>8.82 ± 2.08</td>
<td>27.11 ± 9.33</td>
<td>180.99 ± 24.24</td>
<td>0.52 ± 0.09</td>
<td>6.91 ± 1.31</td>
<td>3.11 ± 1.29</td>
<td>3.42 ± 0.37</td>
<td>0.69 ± 0.23</td>
<td>5.59 ± 0.26</td>
<td>26.43 ± 5.87</td>
<td>13.01 ± 2.35</td>
</tr>
<tr>
<td>B (n = 45)</td>
<td>45 (21/24)</td>
<td>63.92 ± 3.98</td>
<td>23.47 ± 2.14</td>
<td>5.41 ± 1.73</td>
<td>6.27 ± 1.76</td>
<td>8.60 ± 1.99</td>
<td>210.94 ± 24.72</td>
<td>0.68 ± 0.19</td>
<td>7.53 ± 1.02</td>
<td>3.32 ± 1.03</td>
<td>3.53 ± 0.63</td>
<td>0.66 ± 0.26</td>
<td>2.38 ± 0.24</td>
<td>20.64 ± 5.04</td>
<td>10.53 ± 1.46</td>
</tr>
<tr>
<td>C (n = 45)</td>
<td>45 (23/22)</td>
<td>66.82 ± 4.92</td>
<td>23.93 ± 2.71</td>
<td>9.89 ± 1.94</td>
<td>10.76 ± 2.02</td>
<td>14.91 ± 6.73</td>
<td>210.94 ± 24.72</td>
<td>0.72 ± 0.31</td>
<td>7.33 ± 1.31</td>
<td>3.21 ± 1.32</td>
<td>3.58 ± 0.77</td>
<td>0.51 ± 0.32</td>
<td>5.62 ± 0.33</td>
<td>14.67 ± 4.24</td>
<td>12.76 ± 1.89</td>
</tr>
<tr>
<td>D (n = 45)</td>
<td>45 (22/23)</td>
<td>66.82 ± 4.92</td>
<td>23.93 ± 2.71</td>
<td>9.89 ± 1.94</td>
<td>10.76 ± 2.02</td>
<td>14.91 ± 6.73</td>
<td>210.94 ± 24.72</td>
<td>0.84 ± 0.33</td>
<td>6.99 ± 1.32</td>
<td>3.26 ± 1.36</td>
<td>3.38 ± 0.47</td>
<td>0.36 ± 0.31</td>
<td>3.37 ± 0.22</td>
<td>9.96 ± 4.24</td>
<td>10.36 ± 1.64</td>
</tr>
<tr>
<td>E (n = 45)</td>
<td>45 (24/21)</td>
<td>64.18 ± 3.99</td>
<td>24.34 ± 2.83</td>
<td>14.39 ± 2.18</td>
<td>12.99 ± 2.09</td>
<td>5.03 ± 3.75</td>
<td>26.04 ± 25.99</td>
<td>0.87 ± 0.42</td>
<td>7.22 ± 1.21</td>
<td>3.12 ± 1.33</td>
<td>3.72 ± 0.44</td>
<td>0.29 ± 0.27</td>
<td>5.05 ± 0.19</td>
<td>7.18 ± 3.84</td>
<td>12.48 ± 3.03</td>
</tr>
</tbody>
</table>

Groups: NC — normal control group; A — patients with pure T2DM; B — patients with bone mass reduction; C — patients with T2DM + bone mass reduction; D — patients with OP; E — patients with T2DM + OP; BMI — body mass index; HbA₁c — haemoglobin; FPG — fasting plasma glucose; PINP — N-terminal propeptide of type I procollagen; OPG — osteoprotegerin; β-CTX — β-collagen degradation products; TC — total cholesterol; TG — triglycerides; LDL-C — low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein cholesterol; HOMA-IR — homeostasis model of assessment for insulin resistance index; 25(OH)D — 25-hydroxyvitamin D; FINS — fasting plasma insulin; T2DM — type 2 diabetes mellitus; OP — osteoporosis.

Note: vs. group NC; 1p < 0.05; vs. group A, 2p < 0.05; vs. group B, 3p < 0.05; vs. group C, 4p < 0.05; vs. group D, 5p < 0.05.

Figure 1A. Comparison of serum levels of 25-hydroxyvitamin D (25(OH)D) among groups; B. Comparison of serum osteoprotegerin (OPG) levels among groups.
12. Compared with group NC, BSP mRNA in the peripheral blood was significantly downregulated in group C (p < 0.05).
13. Compared with group E, BSP mRNA in the peripheral blood was significantly upregulated in group D (p < 0.05).
14. Compared with group NC, BSP mRNA in the peripheral blood was significantly downregulated in group D (p < 0.05) (Tab. 3, Fig. 2).

Comparison of BMD
1. The comparison of BMD in the Ward’s triangle and total hip was not statistically significant among groups (p > 0.05).
2. Compared with group B, BMD of L1–L4 and left femoral neck was significantly increased in group A (p < 0.05).
3. Compared with group C, BMD of L1–L4 and left femoral neck was significantly increased in group A (p < 0.05).
4. Compared with group D, BMD of L1–L4 and left femoral neck was significantly increased in group A (p < 0.05).
5. Compared with group E, BMD of L1–L4 and left femoral neck was significantly increased in group A (p < 0.05).
6. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly decreased in group A (p < 0.05).
7. Compared with group C, BMD of L1–L4 and left femoral neck was significantly increased in group B (p < 0.05).
8. Compared with group D, BMD of L1–L4 and left femoral neck was significantly increased in group B (p < 0.05).
9. Compared with group E, BMD of L1–L4 and left femoral neck was significantly increased in group B (p < 0.05).
10. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly decreased in group B (p < 0.05).
11. Compared with group D, BMD of L1–L4 and left femoral neck was significantly decreased in group C (p < 0.05).
12. Compared with group E, BMD of L1–L4 and left femoral neck was significantly decreased in group C (p < 0.05).
13. Compared with group E, BMD of L1–L4 and left femoral neck was significantly increased in group D (p < 0.05).
14. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly decreased in group D (p < 0.05).
15. Compared with group NC, BMD of L1–L4 and left femoral neck was significantly decreased in group E (p < 0.05) (Tab. 4).

Results of Pearson correlation analysis
There was no statistical correlation in the level of BSP mRNA in peripheral blood with the age, FPG, BMI, TC, TG, LDL-C, FIns, or HOMA-IR (p > 0.05); the level of BSP mRNA in peripheral blood was negatively correlated with β-CTX, HbA1c, and OPG (correlation coefficients r were −0.483, −0.474, and −0.527, respectively, p < 0.05) (Tab. 2); the level of BSP mRNA in peripheral blood was positively correlated with 25(OH)D, PINP, and 25(OH)D.
Endokrynologia Polska 2020; 71 (2)

Table 5. Correlative analysis of bone sialoprotein (BSP) mRNA level in peripheral blood and clinical biochemical indexes (r)

<table>
<thead>
<tr>
<th>Item</th>
<th>BSP mRNA r</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>25(OH)D</td>
<td>0.425</td>
<td>0.035</td>
</tr>
<tr>
<td>PINP</td>
<td>0.477</td>
<td>0.041</td>
</tr>
<tr>
<td>HDL-C</td>
<td>0.626</td>
<td>0.036</td>
</tr>
<tr>
<td>OPG</td>
<td>-0.527</td>
<td>0.039</td>
</tr>
<tr>
<td>β-CTX</td>
<td>-0.483</td>
<td>0.027</td>
</tr>
<tr>
<td>HbA1c</td>
<td>-0.474</td>
<td>0.019</td>
</tr>
</tbody>
</table>

25(OH)D — 25-hydroxyvitamin D; PINP — N-terminal propeptide of type I procollagen; HDL-C — high-density lipoprotein cholesterol; OPG — osteoprotegerin; β-CTX — β-collagen degradation products; HbA1c — haemoglobin.

Table 4. Comparison of bone mineral density (BMD) among groups

<table>
<thead>
<tr>
<th>Group</th>
<th>L1–L4 [g/cm²]</th>
<th>Left femoral neck [g/cm²]</th>
<th>Ward’s triangle [g/cm²]</th>
<th>Total hip [g/cm²]</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC</td>
<td>1.42 ± 0.20</td>
<td>1.27 ± 0.17</td>
<td>0.61 ± 0.13</td>
<td>0.78 ± 0.12</td>
</tr>
<tr>
<td>A</td>
<td>1.33 ± 0.18¹</td>
<td>1.03 ± 0.13²</td>
<td>0.59 ± 0.11</td>
<td>0.75 ± 0.11</td>
</tr>
<tr>
<td>B</td>
<td>1.22 ± 0.14¹</td>
<td>0.97 ± 0.09¹</td>
<td>0.61 ± 0.08</td>
<td>0.80 ± 0.09</td>
</tr>
<tr>
<td>C</td>
<td>1.19 ± 0.11³</td>
<td>0.87 ± 0.07³</td>
<td>0.60 ± 0.09</td>
<td>0.78 ± 0.13</td>
</tr>
<tr>
<td>D</td>
<td>0.88 ± 0.08¹</td>
<td>0.68 ± 0.06¹</td>
<td>0.58 ± 0.10</td>
<td>0.81 ± 0.08</td>
</tr>
<tr>
<td>E</td>
<td>0.69 ± 0.06³</td>
<td>0.45 ± 0.05³</td>
<td>0.62 ± 0.12</td>
<td>0.79 ± 0.10</td>
</tr>
</tbody>
</table>

Groups: NC — normal control group; A — patients with pure T2DM; B — patients with bone mass reduction; C — patients with T2DM + bone mass reduction; D — patients with OP; E — patients with T2DM + OP.

Note: vs. group NC, ¹p < 0.05; vs. group A, ²p < 0.05; vs. group B, ³p < 0.05; vs. group C, ⁴p < 0.05; vs. group D, ⁵p < 0.05

Table 6. Logistic regression analysis of risk factors associated with osteoporosis (OP) in patients with type 2 diabetes mellitus (T2DM)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Regression coefficient</th>
<th>Waldχ²</th>
<th>p</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td>3.162</td>
<td>25.342</td>
<td>0.037</td>
<td>6.632 (2.534–11.546)</td>
</tr>
<tr>
<td>BSP mRNA</td>
<td>7.352</td>
<td>3.353</td>
<td>0.025</td>
<td>7.135 (2.174–9.234)</td>
</tr>
<tr>
<td>β-CTX [μg/L]</td>
<td>3.423</td>
<td>5.097</td>
<td>0.043</td>
<td>4.324 (3.313–7.291)</td>
</tr>
<tr>
<td>OPG [ng/L]</td>
<td>5.211</td>
<td>3.119</td>
<td>0.041</td>
<td>3.391 (1.192–9.273)</td>
</tr>
<tr>
<td>25(OH)D [ng/mL]</td>
<td>-0.931</td>
<td>5.128</td>
<td>0.017</td>
<td>0.425 (0.219–0.816)</td>
</tr>
<tr>
<td>PINP [μg/L]</td>
<td>-0.169</td>
<td>1.326</td>
<td>0.021</td>
<td>0.226 (0.021–0.332)</td>
</tr>
<tr>
<td>HDL-C [mmol/L]</td>
<td>-0.417</td>
<td>2.324</td>
<td>0.039</td>
<td>0.761 (0.012–0.827)</td>
</tr>
</tbody>
</table>

HbA1c — haemoglobin; BSP — bone sialoprotein; β-CTX — β-collagen degradation products; OPG — osteoprotegerin; 25(OH)D — 25-hydroxyvitamin D; PINP — N-terminal propeptide of type I procollagen; HDL-C — high-density lipoprotein cholesterol.

Discussion

OP is a metabolic bone disease that causes bone fragility and proneness to fracture. Due to the increasing incidence in recent years, it has become a major disease that plagues the world [10]. T2DM is closely related to OP [11]. In recent years, studies have reported that BSP mRNA expression is closely related to DM and OP [12]. However, the expression of BSP mRNA in peripheral blood of T2DM patients with different bone mass has not been reported in China and abroad. Therefore, this study intended to compare the expression of BSP mRNA, 25(OH)D, PINP, and OPG in regulating glycometabolism, lipid metabolism, and bone mass, thus providing new insights into the mechanisms of BSP mRNA, 25(OH)D, and OPG in T2DM patients with OP (Tab. 6).
ideas for early clinical prevention and treatment of DM and OP.

BSP is a kind of highly glycosylated, phosphorylated, and sulphated non-collagen protein containing a large amount of sialic acid and is mainly secreted and expressed by osteoblasts, osteoclasts, and cartilage tissue cells. BSP is specifically localized in bone tissues and plays a role in regulating the function of bone tissues [13]. Vitamin D plays an important role in bone metabolism. The main function of VD is to maintain normal blood calcium and phosphorus levels and to promote normal bone mineralisation [14]. Because 25(OH)D is relatively high in blood and has a longer half-life, the level of 25(OH)D is generally clinically determined so as to reflect the VD level in humans [15]. Osteoprotegerin plays a specific role in bone tissue and is a key determinant factor affecting the differentiation and maturation of osteoclasts, as well as regulating bone metabolism [16]. Osteoprotegerin inhibits the differentiation and maturation of osteoclasts, prevents excessive bone absorption, and plays a specific role in bone protection [17]. Studies have found that the serum OPG level in women aged 48–65 years is significantly high, indicating that the level in menopausal women is higher than that in non-menopausal women. It is speculated that the osteoclast function is active when oestrogen is deficient, resulting in bone resorption increase, bone loss acceleration, stimulated body compensatory bone formation increase, and corresponding increase in serum OPG [18]. b-collagen degradation products and PINP represent bone resorption and bone formation, respectively, and are commonly used biochemical indicators for reflecting bone transformation [19, 20]. Factors such as hyperglycaemia, low HDL-C, hypertension, or endothelial injury can affect the expression of BSP mRNA [21]. This study also reveals that plasma 25(OH)D, PINP, and HDL-C are positively correlated with the expression of BSP mRNA in peripheral blood, which can presume that glucose- and lipid-metabolism disorder, as well as low levels of BSP mRNA and 25 (OH) D in peripheral blood, can more easily induce OP. Therefore, decreased serum VD level, elevated OPG, and decreased expression of BSP mRNA in peripheral blood may be risk factors for predicting T2DM with OP.

Conclusions

Patients with T2DM and OP are often combined with lipid metabolism disorder, serum 25(OH)D level reduction, and gradual reduction of BSP mRNA expression in peripheral blood, resulting in loss of bone mass; vice versa, bone loss will further aggravate glucose- and lipid-metabolism disorder, which forms a vicious circle. Therefore, active VD supplementation may break this vicious circle. The decrease of 25(OH)D in serum may be involved in the development of DM and OP by down-regulating the expression of BSP mRNA in peripheral blood. Therefore, patients with T2DM should not only increase blood glucose control but also pay attention to serum 25(OH)D and BSP mRNA expression in peripheral blood, which may have a certain preventive effect on the prevention and treatment of DM and OP, but its specific mechanism needs further research and exploration.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (Project No. 81460168); Subsidiary project for New Seedling Cultivation and Innovation Exploration of Zunyi Medical College (No. QKHRC[2017]5733-043); Joint Foundation of Zunyi (No. Zhengshi KHS [2018]63); Guizhou Provincial Natural Science Foundation (QKH-J [2020]1Y314).

Conflicts of interest

The authors declare no conflict of interest.

References


